1. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study
- Author
-
Pierre Hirsch, Jérôme Lambert, Maxime Bucci, Caroline Deswarte, Augustin Boudry, Juliette Lambert, Laurene Fenwarth, Jean-Baptiste Micol, Christine Terré, Karine Celli-Lebras, Xavier Thomas, Hervé Dombret, Nicolas Duployez, Claude Preudhomme, Raphael Itzykson, and Francois Delhommeau
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract The evaluation of measurable residual disease (MRD) in acute myeloid leukemia (AML) using comprehensive mutation analysis by next-generation sequencing (NGS) has been investigated in several studies. However controversial results exist regarding the detection of persisting mutations in DNMT3A, TET2, and ASXL1 (DTA). Benchmarking of NGS-MRD taking into account other molecular MRD strategies has to be done. Here, we performed error-corrected-NGS-MRD in 189 patients homogeneously treated in the ALFA-0702 study (NCT00932412). Persistence of non-DTA mutations (HR = 2.23 for RFS and 2.26 for OS), and DTA mutations (HR = 2.16 for OS) were associated with poorer prognosis in multivariate analysis. Persistence of at least two mutations in complete remission (CR) was associated with a higher cumulative incidence of relapse (CIR) (HR = 3.71, p
- Published
- 2024
- Full Text
- View/download PDF